Syneos Health, Inc. (NASDAQ: SYNH) Securities Fraud Class Action

Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Syneos Health, Inc. (“Syneos”) (NASDAQ: SYNH) common stock between September 9, 2020 and November 3, 2022, inclusive (the “Class Period”).

Syneos is an “end-to-end” biopharmaceutical solutions provider offering services from early-phase clinical trials to the commercialization of a product.

The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Syneos was facing quality issues that were reported late at Syneos and were not communicated in a timely manner to clients; (2) Syneos’s audit inspections and root cause analyses had not been effective in correcting the recurring quality issues; (3) quality was not embedded in the day-to-day execution at Syneos; and (4) as a result of the foregoing, Defendants’ statements about Syneos’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Current Status of Case:
On March 31, 2026, the Court granted in part and denied in part Defendants’ Motion to Dismiss the Amended Complaint. This action is in the discovery phase and is ongoing.

If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at [email protected]. If you would like additional information about the suit, please click on the link “Submit Your Information” above and fill out the form as promptly as possible.